Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides branded, OTC, and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, immunology, pain management, hypertension, central nervous system, cardiology, diabetes, contraceptives, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays. Its product pipeline includes ISB 2001, a CD38 x BCMA x CD3 TREAT trispecific T cell engager, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 2301, a NK cell engager that is in preclinical trial for solid tumors; and GRC 65327, a Cbl-b inhibitor small molecule for solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 1 clinical trial for the treatment of hidradenitis suppurativa; and ISB 830-X8, a telazorlimab OX40 antagonist antibody that is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.
Low
1,792.60
High
2,474.00
Low
0.00
High
2,348.60
Company's profit divided by outstanding shares.
Ratio of share price to its earnings per share.
Total number of outstanding shares.
Gap between today's open and yesterday's close.
Average daily traded volume.
Highest price reached in the last 30 days.
Lowest price reached in the last 30 days.
Highest price reached in the last six months.
Lowest price reached in the last six months.
Highest price reached in the last year.
Lowest price reached in the last year.
How Glenmark Pharmaceuticals Limited stacks up against its Drug Manufacturers - Specialty & Generic peers on price, valuation and the 52-week range. Tap any column header to sort.
| # | Name | Price | Chg % | P/E | EPS | Mkt Cap (Cr) | 1M % | 1Y % | 52W H/L |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GLENMARK Glenmark Pharmaceuticals Limited | 2,306.20 | 1.14% | 47.81 | 48.23 | 65,087 | 0.12% | 3.51% | 2,474.00 / 1,792.60 |
| 2 | AARTIDRUGS Aarti Drugs Limited | 418.00 | 0.78% | 19.97 | 20.93 | 3,815 | 5.53% | 20.38% | 534.55 / 318.95 |
| 3 | AARTIPHARM Aarti Pharmalabs Limited | 816.10 | 1.59% | 34.73 | 23.50 | 7,400 | 13.69% | 14.28% | 946.10 / 585.00 |
| 4 | ABBOTINDIA Abbott India Limited | 26,250.00 | 0.50% | 34.55 | 759.88 | 55,774 | 0.00% | 23.36% | 0.00 / 25,150.00 |
| 5 | AHCL ANLON HEALTHCARE LIMITED | 14.38 | 0.07% | 5.93 | 2.42 | 764 | 0.00% | 58.02% | 17.27 / 9.08 |
| 6 | AJANTPHARM Ajanta Pharma Limited | 3,650.00 | 0.24% | 40.18 | 90.83 | 45,595 | 0.00% | 30.87% | 3,796.00 / 2,329.90 |
| 7 | AKUMS AKUMS DRUGS AND PHARMA L | 750.00 | 0.39% | 0.00 | 19.05 | 11,483 | 9.97% | 35.62% | 0.00 / 409.30 |
| 8 | ALIVUS Alivus Life Sciences Limited | 1,357.00 | 0.95% | 27.68 | 49.03 | 16,506 | 0.00% | 28.10% | 1,418.00 / 819.00 |
| 9 | ALKEM Alkem Laboratories Limited | 5,395.00 | 0.09% | 0.00 | 0.00 | 64,536 | 2.73% | 7.93% | 5,933.50 / 5,075.00 |
| 10 | AMRUTANJAN Amrutanjan Health Care Limited | 533.25 | 2.22% | 28.56 | 0.00 | — | 0.38% | 23.27% | 790.95 / 482.80 |
| 11 | APLLTD Alembic Pharmaceuticals Limited | 818.75 | 0.57% | 23.22 | 35.27 | 16,150 | 0.15% | 20.51% | 998.00 / 635.80 |
| 12 | ASTRAZEN AstraZeneca Pharma India Limited | 7,400.00 | 0.00% | 109.07 | 67.85 | 18,500 | 0.00% | 18.49% | 9,849.50 / 7,371.50 |
| 13 | AUROPHARMA Aurobindo Pharma Limited | 0.00 | 0.43% | 25.23 | 64.00 | 92,918 | 100.00% | 100.00% | 1,682.40 / 1,016.10 |